Figure 2.
Average platelet counts and standard error of the mean in relation to the start of caplacizumab treatment. Average platelet counts (A) and lactate dehydrogenase (B) and standard error of the mean in relation to the start of caplacizumab treatment. The x-axis (time in days) denotes the time elapsed since the start of caplacizumab and not since the initial diagnosis (ie, day 0). Please note that there is no fixed correlation between the beginning of caplacizumab and the beginning of the treatment, because caplacizumab was not used as a frontline agent in a relevant number of instances. Green dotted lines indicate upper limit of normal (ULN) or lower limit of normal (LLN).